Literature DB >> 30412694

The current clinical and geographical situation of cutaneous leishmaniasis based on species identification in Turkey.

Ahmet Özbilgin1, Seray Töz2, Mehmet Harman3, Suhan Günaştı Topal4, Soner Uzun5, Fulya Okudan6, Dilek Güngör4, Ayşegül Erat5, Hatice Ertabaklar7, Sema Ertuğ7, Cumhur Gündüz8, İbrahim Çavuş1, Mehmet Karakuş2, İpek Östan Ural9, M Kirami Ölgen10, Çağla Kayabaşı8, Özgür Kurt11, Yusuf Özbel12.   

Abstract

Leishmaniases are a group of vector-borne diseases caused by the members of Leishmania genus, and there are three main clinical forms of the infection as visceral, cutaneous, and mucocutaneous. Cutaneous leishmaniasis is a growing public health problem in Turkey due to increasing detection of autochthonous cases caused by L. major and L. donovani in some regions in addition to Syrian imported cases. For this reason, we aimed to evaluate the current epidemiological situation of CL in the view of causative agents and their geographical distribution throughout Turkey. The samples were collected from 356 CL patients admitted to different centers in 18 provinces between January 2013 and December 2016. Direct microscopy, culture (regular and enriched NNN) and molecular techniques (real-time ITS1 PCR and hsp70 PCR/sequencing) were performed. By molecular techniques, 299, 28, 19 and 10 isolates/clinical samples were identified as L. tropica, L. major, L. infantum and L. donovani, respectively. Most of the patients (65.73%) had one lesion usually on their face/head. Dry-nodular type lesions (n = 291) were mainly associated with L. tropica while L. major was mainly found related to wet-ulcerative ones. Leishmaniasis recidivans was also detected in 2.52% among 356 patients. L. tropica was detected as most widespread species causing CL in Turkey. L. infantum and L. major was also found in one third of the provinces. Enriched NNN culture was worked well for isolating the parasite and 346 isolates were successfully grown and stored in liquid nitrogen. The comparison of all diagnostic techniques showed that the parasitological positivity rate could increase if the combination of direct microscopy and real-time ITS1 PCR is used. Besides well-known anthroponotic L. tropica cases, the increasing detection of CL cases caused by zoonotic species, L. infantum and L. major, is one of the most important findings in the present study. In our opinion to ensure timely and accurate diagnosis, proper treatment and countrywide effective control of CL in Turkey a systematic approach is needed on the base of information about characteristics of lesions and patients and epidemiological features of the disease.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinic; Cutaneous; Epidemiology; Leishmaniasis; Turkey

Mesh:

Year:  2018        PMID: 30412694     DOI: 10.1016/j.actatropica.2018.11.001

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  3 in total

1.  Blood Meal Analysis and Molecular Detection of Leishmania DNA in Wild-Caught Sand Flies in Leishmaniasis Endemic Areas of Turkey and Northern Cyprus.

Authors:  Kardelen Yetişmiş; Ufuk Mert; Ayşe Caner; Muhammed Nalçaci; Seray Töz; Yusuf Özbel
Journal:  Acta Parasitol       Date:  2022-04-06       Impact factor: 1.440

2.  The Investigation of the Association of Cutaneous Leishmaniasis in Biopsy Specimens of the Patients with Granulomatous Disease and Skin Cancer Using the Molecular Method.

Authors:  Gülnaz Çulha; Asena Çiğdem DoĞramaci; Sibel Hakverdİ; İlke Evrim SeÇİntİ; Özkan AslantaŞ; Ebru Çelİk; Tuğba Kaya
Journal:  Iran J Parasitol       Date:  2020 Jul-Sep       Impact factor: 1.012

Review 3.  The current epidemiology of leishmaniasis in Turkey, Azerbaijan and Georgia and implications for disease emergence in European countries.

Authors:  Yusuf Özbel; Seray Töz; Clara Muñoz; Maria Ortuño; Zarima Jumakanova; Pedro Pérez-Cutillas; Carla Maia; Cláudia Conceição; Gad Baneth; André Pereira; Yves Van der Stede; Céline M Gossner; Eduardo Berriatua
Journal:  Zoonoses Public Health       Date:  2022-05-26       Impact factor: 2.954

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.